| Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? | |
| | |
MedLine Citation:
|
PMID: 19149529 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs) have been prescribed extensively, often in combination with each other. When toxic encephalopathy develops with neuromuscular and autonomic symptoms in a patient taking medication including atypical antipsychotics, it has tended to be diagnosed as neuroleptic malignant syndrome (NMS). However, there have recently been several case reports where the diagnosis of serotonin syndrome is given or raised as a likely differential diagnosis to such cases. In the present review, the author addressed himself to the issues surrounding the neurotoxic reaction to the treatment regimen containing atypical antipsychotics, focusing on the "atypical" forms of NMS and pathophysiological as well as clinical features of serotonin toxicity. Although NMS is idiosyncratic in nature, it appears practically useful to comprehend this syndrome as a spectrum-based concept. Likewise, serotonin toxicity is a broad spectrum of clinical syndromes in close connection with serotomimetic drug use, including varied severity. Some of atypical antipsychotics, i.e., perospirone, aripiprazole, ziprasidone, clozapine, and quetiapine, have been shown to behave as partial agonists at 5-HT1A receptors, providing direct evidence that these atypical antipsychotics are serotomimetic per se. The reciprocal interaction between the dopaminergic and serotonergic systems disturbed by either dopaminergic blockers or serotonergic enhancers leads to the disruption of homeostasis, with typical forms of NMS and serotonin syndrome representing the ends of the common pathophysiological background. The practical and flexible way to consider and manage such cases with updated knowledge derived from basic research should be warranted to be beneficial to our patients. |
| | |
Authors:
|
Yuji Odagaki |
Related Documents
:
|
17939319 - Mirizzi syndrome caused by a bile pseudocyst. 10531189 - Advanced heart block as a manifestation of a paraneoplastic syndrome from malignant thy... 378049 - Allergic bronchopulmonary aspergillosis-like syndrome consequent to aspergilloma. 4046919 - Vincristine neurotoxicity in charcot-marie-tooth syndrome. 8009269 - A fulminant case of neuroleptic malignant syndrome. 10584199 - Association of inflammatory pseudotumor of the liver and papillon-lefevre syndrome--cas... 6562959 - Apheresis. 3690909 - Accessory atrioventricular pathway, supra-, and infrahisian conduction impaired due to ... 2985019 - Fanconi's anemia, medulloblastoma, wilms' tumor, horseshoe kidney, and gonadal dysgenesis. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current drug safety Volume: 4 ISSN: 1574-8863 ISO Abbreviation: - Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-19 Completed Date: 2009-03-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101270895 Medline TA: Curr Drug Saf Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 84-93 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Faculty of Medicine, Saitama Medical University, Saitama, Japan. odagaki@saitama-med.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antipsychotic Agents / adverse effects* Humans Neuroleptic Malignant Syndrome / diagnosis, etiology*, physiopathology Receptor, Serotonin, 5-HT1A / agonists Serotonin Agonists / adverse effects Serotonin Syndrome / chemically induced*, diagnosis, physiopathology Serotonin Uptake Inhibitors / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Serotonin Agonists; 0/Serotonin Uptake Inhibitors; 112692-38-3/Receptor, Serotonin, 5-HT1A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biodegradable polymer-metal complexes for gene and drug delivery.
Next Document: Biomarkers, critical disease pathways, drug targets, and alternative medicine in male breast cancer.